Rhythm Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $239.9M+84.4% YoYTTM through 30 Jun 2026
Net Income -$205.3MTTM through 30 Jun 2026
Free Cash Flow -$106.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 87.4% |
| EBITDA Margin | -83.3% |
| Operating Margin | -98.6% |
| Net Margin | -85.6% |
Returns
-74.8%ROE
-42.0%ROA
Balance Sheet Health
Debt / Equity0.01x
Current Ratio4.17x
Net Debt-$385Mnet cash position
Cash & Equivalents$65.6M
Quality Metrics
Altman Z-Score13.85
Piotroski F-Score4 / 9
FCF Margin-44.3%
Rule of 40-13.6
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $189.8M
Diluted EPS-$3.12TTMFY2025: $-3.02
Dividend
No dividend
Capital Allocation
R&D Spend$173.2M
Capex Intensity0.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| IMCIVREE (setmelanotide) Net Product Sales | $194.8M | +49.7% | View detailsGrowth is expected to continue driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO) following FDA approval on March 19, 2026, alongside continued geographic expansion. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.